| Name | Entacapone |
| Description | Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor with an IC50 of 151 nM. Entacapone is also a potential obesity-related gene (FTO) inhibitor that can inhibit FTO demethylation activity and be used in the study of metabolic diseases. |
| In vivo | In various tissues, such as the liver, duodenum, kidney, and lung, Entacapone inhibits the activity of catechol-O-methyltransferase (COMT). Additionally, in PC12 cells, Entacapone can suppress extracellular cytotoxicity induced by the aggregation of α-syn and β-amyloid (Aβ). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (818.89 mM), Sonication is recommended. Ethanol : 2 mg/mL (6.55 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.55 mM), Sonication is recommended.
|
| Keywords | Parkinson's disease | OR611 | OR 611 | metabolic disorder | Inhibitor | inhibit | Entacapone | COMT | ?FTO?knockdown |
| Inhibitors Related | Alendronate sodium trihydrate | Serotonin hydrochloride | Serotonin | Rosmarinic acid | D(+)-Raffinose pentahydrate | Risedronic Acid | 3-Methoxybenzamide | CBHcy | (-)-Gallocatechin gallate | Eliglustat hemitartrate | Flopropione | Tolcapone |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Approved Drug Library | EMA Approved Drug Library | Anti-Parkinson's Disease Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |